Nitroxoline (Asieris Pharmaceuticals)

Tier C — Watch / trade

Originator

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：METAP2

Brand：Vesique

Indications (approved)：Bladder cancer, 阿米巴感染

Regional status

Phase II

2021-12-28

China

Phase III

2021-09-29

Japan

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 2 · Total yield /

Nitroxoline-001148-24-3API · Nitroxoline (Asieris Pharmaceuticals)

Code	CAS No.	Intermediate
Nitroxoline-001	148-24-3	quinolin-8-ol

Frequently asked questions

What are the approved indications of Nitroxoline (Asieris Pharmaceuticals)?

Approved indications include: Bladder cancer, 阿米巴感染.

When does the Nitroxoline (Asieris Pharmaceuticals) patent expire?

No public expiry year is available for Nitroxoline (Asieris Pharmaceuticals) yet; this page updates once verified.

How many synthesis routes are recorded for Nitroxoline (Asieris Pharmaceuticals)?

1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Nitroxoline (Asieris Pharmaceuticals) intermediates?

All intermediates in Nitroxoline (Asieris Pharmaceuticals) routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.

How do I get a quote for Nitroxoline (Asieris Pharmaceuticals) intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-06